Article
Chemistry, Multidisciplinary
Xiao Yang, Yuan Cheng, Jingyi Zhou, Lingpu Zhang, Xingchen Li, Zhiqi Wang, Shenyi Yin, LiRong Zhai, Ting Huang, Xiaotong Wu, Boqiang Shen, Yangyang Dong, Lijun Zhao, Yujing Chi, Yuanyuan Jia, Jiaqi Wang, Yijiao He, Xiying Dong, Haihua Xiao, Jianliu Wang
Summary: This study found that diabetes is closely related to endometrial cancer and there is currently no effective treatment for patients with both conditions. Through experiments, a new drug (JX06-NPs) that disrupts cancer metabolism was discovered to significantly inhibit the growth of endometrial cancer cells, with better results when combined with metformin. This study provides a new adjuvant therapy for patients with diabetes and endometrial cancer.
Article
Oncology
Chelsea Anderson, Andrew F. Olshan, Victoria L. Bae-Jump, Wendy R. Brewster, Jennifer L. Lund, Hazel B. Nichols
Summary: This study reveals a high burden of cardiovascular disease (CVD) diagnoses among endometrial cancer (EC) survivors and highlights the importance of managing pre-existing CVD and monitoring for incident CVD during EC treatment and long-term survivorship.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Endocrinology & Metabolism
Jun Guan, Xiao-Jun Chen
Summary: Progestin therapy is the main treatment for preserving fertility in women with endometrial cancer and atypical endometrial hyperplasia. Studies suggest that metformin may have potential benefits in improving the therapeutic outcome of progestin treatment. However, there is still a lack of strong evidence supporting the use of metformin in this context due to heterogeneity and design limitations in existing studies.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Oncology
Lauren McVicker, Christopher R. Cardwell, Lauren Edge, W. Glenn McCluggage, Declan Quinn, James Wylie, Una C. McMenamin
Summary: This study, through a systematic review and meta-analysis, found that diabetes is associated with worse cancer-specific and overall survival in endometrial cancer patients.
Article
Nutrition & Dietetics
Giovanna Esposito, Francesca Bravi, Diego Serraino, Fabio Parazzini, Anna Crispo, Livia S. A. Augustin, Eva Negri, Carlo La Vecchia, Federica Turati
Summary: The study found that following a diabetes risk reduction diet may reduce the risk of endometrial cancer. Combining high vegetable consumption with high adherence to the DRRD may offer additional benefits in preventing endometrial cancer.
Article
Oncology
Elina Urpilainen, Reetta Arima, Peeter Karihtala, Ulla Puistola, Anne Ahtikoski
Summary: The study found that metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D, such as type 2 histology, deep myometrial invasion, and lymphovascular invasion, but showed no association with overall survival and progression-free survival.
ANTICANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Chun-Jung Chen, Chih-Cheng Wu, Cheng-Yi Chang, Jian-Ri Li, Yen-Chuan Ou, Wen-Ying Chen, Su-Lan Liao, Jiaan-Der Wang
Summary: The study found that metformin can alleviate tumor growth caused by high-fat diet, inhibit inflammation, and may be a potential treatment for obesity-related cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Sebastian Stepien, Pawel Olczyk, Joanna Gola, Katarzyna Komosinska-Vassev, Aleksandra Mielczarek-Palacz
Summary: Due to their multidirectional influence, adipocytokines are currently the subject of numerous intensive studies. Significant impact applies to many processes, both physiological and pathological. Moreover, the role of adipocytokines in carcinogenesis seems particularly interesting and not fully understood. Ongoing research focuses on the role of these compounds in the network of interactions in the tumor microenvironment, with special attention on ovarian and endometrial cancer, and their potential clinical relevance.
Article
Oncology
Junyu Chen, Dongyan Cao, Jiaxin Yang, Mei Yu, Huimei Zhou, Ninghai Cheng, Jinhui Wang, Ying Zhang, Peng Peng, Keng Shen
Summary: Fertility-sparing treatment can achieve promising response in obese patients with endometrial cancer and atypical endometrial hyperplasia. Weight loss of more than 10% has a positive influence on treatment response, recurrence, and pregnancy rates. GnRHa could be a suitable option for obese women.
FRONTIERS IN ONCOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Summer Harvey, Nicolas Wentzensen, Kimberly Bertrand, Amanda Black, Louise A. Brinton, Chu Chen, Laura Costas, Luigino Dal Maso, Immaculata De Vivo, Mengmeng Du, Montserrat Garcia-Closas, Marc T. Goodman, Jessica Gorzelitz, Lisa Johnson, James Lacey, Linda Liao, Loren Lipworth, Jolanta Lissowska, Anthony B. Miller, Kelli O'Connell, Tracy A. O'Mara, Xiao Ou, Julie R. Palmer, Alpa Patel, Sonia Paytubi, Beatriz Pelegrina, Stacey Petruzella, Anna Prizment, Thomas Rohan, Sven Sandin, Veronica Wendy Setiawan, Rashmi Sinha, Britton Trabert, Penelope M. Webb, Lynne R. Wilkens, Wanghong Xu, Hannah P. Yang, Wei Zheng, Megan A. Clarke
Summary: This study evaluated the associations between obesity in young adulthood and adulthood with endometrial cancer risk. The results showed that obesity in both periods was positively associated with endometrial cancer risk, and weight gain was also positively associated with this risk while weight loss was inversely associated.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2023)
Article
Endocrinology & Metabolism
Fengping Shao, Yinguang Li, Yunhe Zhao
Summary: A meta-analysis showed that the combination of metformin and progestin was more effective than progestin alone in improving remission and pregnancy rates in patients with endometrial hyperplasia and early endometrial cancer.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Michelle Ertel, S. Allison Staley, Tam Nguyen, Austin Johnson, Austin Hopkins, Nerlyne Desravines, Johnathon Recknagel, Xinyi Zhang, Xianming Tan, Leslie H. Clark
Summary: The study found that the incidence of medical inoperability in clinical stage I endometrial cancer was 4.6%, with factors such as high body mass index, diabetes, coronary artery disease, and hypertension increasing the risk of inoperability. Despite maximal surgical effort and minimally invasive surgery achieving hysterectomy in over 95% of patients, there was a complication rate of 11.6%.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Bartlomiej Barczynski, Karolina Fraszczak, Jan Kotarski
Summary: Insulin resistance and hyperinsulinemia play a key role in the pathogenesis of type 1 endometrial cancer, which often occurs in overweight or type 2 diabetes patients. The medication metformin, commonly used for type 2 diabetes, shows promising anticancer properties by activating AMPK and inhibiting the mTOR pathways. Studies suggest a potential preventative role of metformin in endometrial cancer, especially in early-stage treatment, but more research is needed to understand its therapeutic role.
JOURNAL OF DRUG TARGETING
(2022)
Article
Medicine, General & Internal
Mariana S. Parahuleva, Julian Kreutz, Gerhild Euler, Dora Terzieva, Amar Mardini, Ekaterina Uchikova, Nikoleta Parahuleva
Summary: Endometrial cancer (EC) is significantly associated with an increased incidence of atrial fibrillation (AF). Women with EC who are obese and younger are more likely to develop AF. Adiponectin (APN) levels may be associated with new-onset AF, especially when adjusted for BMI.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Laure Dossus, Eirini Kouloura, Carine Biessy, Vivian Viallon, Alexandros P. Siskos, Niki Dimou, Sabina Rinaldi, Melissa A. Merritt, Naomi Allen, Renee Fortner, Rudolf Kaaks, Elisabete Weiderpass, Inger T. Gram, Joseph A. Rothwell, Lucie Lecuyer, Gianluca Severi, Matthias B. Schulze, Therese Haugdahl Nost, Marta Crous-Bou, Maria-Jose Sanchez, Pilar Amiano, Sandra M. Colorado-Yohar, Aurelio Barricarte Gurrea, Julie A. Schmidt, Domenico Palli, Claudia Agnoli, Rosario Tumino, Carlotta Sacerdote, Amalia Mattiello, Roel Vermeulen, Alicia K. Heath, Sofia Christakoud, Konstantinos K. Tsilidis, Ruth C. Travis, Marc J. Gunter, Hector C. Keun
Summary: The study suggests that glycine, serine, SM C18:0, and free carnitine levels may represent specific pathways linked to endometrial cancer development. Further analysis shows that SM C18:0 and free carnitine are positively associated with endometrial cancer risk, while glycine and serine are inversely associated with endometrial cancer risk.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Obstetrics & Gynecology
Evelin E. Lara-Molina, Jason M. Franasiak, Diego Marin, Xin Tao, Patricia Diaz-Gimeno, Mireia Florensa, Marta Martin, Emre Seli, Antonio Pellicer
FERTILITY AND STERILITY
(2020)
Article
Oncology
Dimitrios Nasioudis, Madhura Bhadra, Emily M. Ko
GYNECOLOGIC ONCOLOGY
(2020)
Article
Genetics & Heredity
Katherine A. Green, George Patounakis, Michael P. Dougherty, Marie D. Werner, Richard T. Scott, Jason M. Franasiak
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
(2020)
Review
Obstetrics & Gynecology
Mauro Cozzolino, Jason Franasiak, Alessandra Andrisani, Guido Ambrosini, Amerigo Vitagliano
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
(2020)
Article
Obstetrics & Gynecology
Dimitrios Nasioudis, Spyridon A. Mastroyannis, Ashley F. Haggerty, Robert L. Giuntoli, Mark A. Morgan, Emily M. Ko, Nawar A. Latif
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
(2020)
Article
Oncology
Dimitrios Nasioudis, Spyridon A. Mastroyannis, Nawar A. Latif, Emily M. Ko
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Dimitrios Nasioudis, Nawar A. Latif, Fiona Simpkins, Lori Cory, Robert L. Giuntoli, Ashley F. Haggerty, Mark A. Morgan, Emily M. Ko
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
A. Graul, A. Haggerty, C. Stickley, P. Kumar, K. Morales, H. Bogner, R. A. Burger, M. Morgan, E. Ko
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Dimitrios Nasioudis, Sruthi Sakamuri, Emily M. Ko, Ashley F. Haggerty, Robert L. Giuntoli, Robert A. Burger, Mark A. Morgan, Nawar A. Latif
GYNECOLOGIC ONCOLOGY
(2020)
Review
Obstetrics & Gynecology
Benjamin B. Albright, Jade M. Shorter, Spyridon A. Mastroyannis, Emily M. Ko, Courtney A. Schreiber, Sarita Sonalkar
OBSTETRICS AND GYNECOLOGY
(2020)
Article
Genetics & Heredity
Andres Reig, Jason Franasiak, Richard T. Scott, Emre Seli
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
(2020)
Article
Oncology
Dimitrios Nasioudis, Quetrell D. Heyward, Ashley F. Haggerty, Robert L. Giuntoli, Robert A. Burger, Mark A. Morgan, Emily M. Ko, Nawar A. Latif
SURGICAL ONCOLOGY-OXFORD
(2020)
Editorial Material
Obstetrics & Gynecology
Amber M. Klimczak, Jason M. Franasiak
FERTILITY AND STERILITY
(2021)
Review
Obstetrics & Gynecology
Jason M. Franasiak, Diana Alecsandru, Eric J. Forman, Laura C. Gemmell, Jeffrey M. Goldberg, Natalia Llarena, Cheri Margolis, Joop Laven, Sam Schoenmakers, Emre Seli
Summary: Implantation is a critical step in human reproduction, and recurrent implantation failure can result from various factors. Literature discussing this clinical phenomenon is increasing, and there is not a universally agreed-on definition for it.
FERTILITY AND STERILITY
(2021)
Editorial Material
Obstetrics & Gynecology
Andres Reig, Jason M. Franasiak
FERTILITY AND STERILITY
(2022)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)